Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants

@article{Moll1997MonitoringWT,
  title={Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants},
  author={Stephan Moll and Thomas L. Ortel},
  journal={Annals of Internal Medicine},
  year={1997},
  volume={127},
  pages={177-185}
}
The incidence of clinically recognized first-event deep venous thrombosis in the United States is approximately 250 000 cases per year [1-3]. Two prospective studies found lupus anticoagulants in 8.5% and 14%, respectively, of patients who presented with venous thromboembolism for the first time [4, 5]. Venous thromboembolic disease associated with lupus anticoagulants may therefore occur in as many as 35 000 patients in the United States annually. Oral anticoagulant therapy with warfarin is… Expand
71 Citations
Differences in the INR evaluation of two different thromboplastins in patients with positivity to lupus anticoagulant in ongoing oral anticoagulation
TLDR
The data confirm that INR evaluation does not reveal significant changes also if tested with two different thromboplastins, for patients ongoing OA with and without LAC positivity, when the INR value is < than 4.5 and a change in the therapeutic approach for OA is possible in these cases. Expand
Monitoring anticoagulation in patients with an unreliable prothrombin time/international normalized ratio: factor II versus chromogenic factor X testing
TLDR
CFX and FII activity are well correlated in patients that require alternative monitoring of warfarin and either test can be used in this population. Expand
Venous Thrombosis in the Antiphospholipid Syndrome
TLDR
The antiphospholipid syndrome is a relatively common acquired cause of venous thrombosis and its antibodies have been shown to directly contribute to hypercoagulability in animal models and in various in vitro studies. Expand
Lupus anticoagulant, warfarin, and alternative laboratory monitoring of anticoagulation
TLDR
A 53 year old woman was evaluated for recurrent native and prosthetic mitral valve thromboembolism in the setting of antiphospholipid antibody syndrome and found to have a persistently high titer of anticardiolipin antibodies. Expand
Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism
  • C. Kearon
  • Medicine
  • Current opinion in hematology
  • 2012
TLDR
Routine thrombophilia testing of patients with VTE is not indicated as a way to guide treatment decisions, because Observational studies indicate that anticoagulants are equally effective in patients with and without thromBophilia; therefore, the presence of throm bophilia should not influence the choice of antICOagulant or the intensity of therapy. Expand
Cancer and Thrombosis: Mechanisms and Treatment
  • S. Deitcher
  • Medicine
  • Journal of Thrombosis and Thrombolysis
  • 2004
TLDR
Low-molecular weight heparins (LMWHs) have been shown to be at least as effective and safe for initial anticoagulation compared with UFH in persons with acute VTE and have gained popularity in the setting of VTE in cancer. Expand
Laboratory monitoring of new anticoagulants
Maintaining a balance between bleeding and clotting has always been a challenge in treating coagulation disorders. A perturbation in that balance can be associated with substantial morbidity andExpand
LETTERS TO THE EDITOR: More on: intensity of warfarin anticoagulation in APS
  • N. Key
  • Medicine
  • Journal of thrombosis and haemostasis : JTH
  • 2005
TLDR
The study suggests that the use of anticoagulant treatment in CABG patients is not associated with an increased risk of intrapericardial bleeding and that full dose antithrombotic therapy is therefore sufficiently safe. Expand
Lupus anticoagulant syndrome: a case report.
TLDR
This case discussion focuses on the recognition and treatment of thrombotic events in the setting of APS, a hypercoagulable state in which autoantibodies are formed against anionic phospholipid complexes. Expand
Pathology consultation on anticoagulation monitoring: factor X-related assays.
TLDR
A case-based approach is used to review pertinent published literatures and product inserts of anticoagulation drugs and to look back on clinical use of factor X-related chromogenic assays, focusing on the differences in test designs and clinical utilities between the chromogenic anti-Xa and chromogenic factor X activity assays. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
Deep venous thrombosis and lupus anticoagulant. A case-control study.
TLDR
LA is significantly associated with DVT in symptomatic patients and further studies are needed to establish the clinical implications of this association. Expand
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
TLDR
Recurrent thrombosis is a potentially serious problem for patients with lupus anticoagulant or anticardiolipin antibodies or both and intermediate- to high-intensity warfarin therapy or aspirin therapy may confer better antithrombotic protection. Expand
The International Normalized Ratio (INR) for Monitoring Warfarin Therapy: Reliability and Relation to Other Monitoring Methods
Reporting prothrombin times used to monitor warfarin therapy as an international normalized ratio (INR) has been proposed as a way to eliminate interlaboratory differences in test results caused byExpand
Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state.
TLDR
The hypothesis that the presence of ACA in SLE patients is associated with an ongoing prothrombotic state is supported by the results of this study. Expand
Biological and clinical heterogeneity of lupus and lupus-like anticoagulant in fifty-seven patients.
TLDR
An extensive study of coagulation profile compared different assays to investigate lupus-like inhibitor: the most sensitive assay was the partial thromboplastin time performed without activator, and when performed with kaolin, it was the only assay detecting the l upus cofactor. Expand
The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant.
TLDR
The findings suggest that LLAC is a non-exceptional cause of prolonged coagulation screening tests, and that it may sometimes be associated with impaired haemostasis. Expand
Antiphospholipid antibodies and venous thromboembolism.
TLDR
The presence of APLA in patients with VTE was not associated with resistance to a conventional intensity of warfarin or an increased risk of recurrent VTE after discontinuation of warFarin, and a larger study should address these issues in a subgroup of patients withVTE and LA. Expand
The lupus anticoagulant/antiphospholipid syndrome.
TLDR
Current methods of diagnosis, concepts of pathogenesis, and the basis for an approach to anticoagulation in patients at risk for thrombosis or other manifestations of the antiphospholipid syndrome are reviewed. Expand
Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic Warfarin therapy
TLDR
Plasma levels of the vitamin K-dependent coagulation factors are not equal in patients on chronic Warfarin therapy, and alternative means of monitoring that more accurately reflects prothrombin levels should be evaluated. Expand
The management of thrombosis in the antiphospholipid-antibody syndrome.
TLDR
The risk of recurrent thrombosis in patients with the antiphospholipid-antibody syndrome is high and long-term anticoagulation therapy in which the international normalized ratio is maintained at or above 3 is advisable in these patients. Expand
...
1
2
3
4
...